Blog
About

0
views
0
recommends
+1 Recommend
1 collections
    0
    shares
      • Record: found
      • Abstract: found
      • Article: found

      Blood and Peritoneal Levels of Endothelin in Continuous Ambulatory Peritoneal Dialysis Patients

      Read this article at

      ScienceOpenPublisherPubMed
      Bookmark
          There is no author summary for this article yet. Authors can add summaries to their articles on ScienceOpen to make them more accessible to a non-specialist audience.

          Abstract

          We have determined the plasma levels of endothelin-1 (ET-1) in patients with end-stage renal disease treated with continuous ambulatory peritoneal dialysis (CAPD). In 10 CAPD patients mean plasma ET levels (7.01 ± 0.5 pg/ml) were found higher than in normal subjects (3.6 ± 0.6 pg/ml). Peritoneal clearance of ET-1 was 1.58 ± 0.12ml/min and 2.3+0.2 ml/min during an isotonic peritoneal exchange and a hypertonic exchange, respectively. Plasma ET-1 levels decreased slightly but significantly during a hypertonic 4-hour exchange (from 7.01 ± 0.5 to 6.14 ± 0.4 pg/ml) (p < 0.05) and were not modified by an isotonic 4-hour exchange (from 5.7 ± 0.5 to 6.4 ± 0.4 pg/ml). ET-1 is known to be an important vascular stimulant and thus elevated ET-1 levels may play a role in the genesis of cardiovascular complications which are the leading cause of mortality in these patients.

          Related collections

          Author and article information

          Journal
          NEF
          Nephron
          10.1159/issn.1660-8151
          Nephron
          S. Karger AG
          1660-8151
          2235-3186
          1995
          1995
          17 December 2008
          : 69
          : 3
          : 273-276
          Affiliations
          Departments of aNephrology and bBiochemistry, Hôpital Pitié-Salpêtrière, Paris, France
          Article
          188469 Nephron 1995;69:273–276
          10.1159/000188469
          7753260
          © 1995 S. Karger AG, Basel

          Copyright: All rights reserved. No part of this publication may be translated into other languages, reproduced or utilized in any form or by any means, electronic or mechanical, including photocopying, recording, microcopying, or by any information storage and retrieval system, without permission in writing from the publisher. Drug Dosage: The authors and the publisher have exerted every effort to ensure that drug selection and dosage set forth in this text are in accord with current recommendations and practice at the time of publication. However, in view of ongoing research, changes in government regulations, and the constant flow of information relating to drug therapy and drug reactions, the reader is urged to check the package insert for each drug for any changes in indications and dosage and for added warnings and precautions. This is particularly important when the recommended agent is a new and/or infrequently employed drug. Disclaimer: The statements, opinions and data contained in this publication are solely those of the individual authors and contributors and not of the publishers and the editor(s). The appearance of advertisements or/and product references in the publication is not a warranty, endorsement, or approval of the products or services advertised or of their effectiveness, quality or safety. The publisher and the editor(s) disclaim responsibility for any injury to persons or property resulting from any ideas, methods, instructions or products referred to in the content or advertisements.

          Page count
          Pages: 4
          Categories
          Original Paper

          Cardiovascular Medicine, Nephrology

          Continuous ambulatory peritoneal dialysis, Endothelin

          Comments

          Comment on this article